Giant cell arteritis - The methotrexate debate revisited [2]

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1458-1459

  Rimar, Doron ^a   Rozenbaum, Michael ^b   Zisman, Devy ^a   Boulman, Nina ^b   Slobodin, Gleb ^b   Eder, Lihi ^a   Feld, Joy ^a   Rosner, Itzhak ^b  

^a CARMEL MEDICAL CENTER   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 12; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

AGED; BLINDNESS; BLOOD CULTURE; BLOOD VESSEL BIOPSY; CASE REPORT; CLAUDICATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GIANT CELL ARTERITIS; HEADACHE; HUMAN; JAW; LETTER; LONG TERM CARE; MALAISE; MALE; OPHTHALMOSCOPY; PRIORITY JOURNAL; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SHOULDER PAIN; STEROID SPARING; SYNOVITIS; TEMPORAL ARTERY; TH1 CELL;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BLINDNESS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PREDNISONE; TEMPORAL ARTERITIS;

EID: 33745802203     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 2003;21 Suppl 32:529-34.
2. Hoffman GS, Cid MC, Hellman DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
3. Jover J, Hernandez-Garcia C, Morado I, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-14.
4. Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis. Clin Exp Rheumatol 2001;19:495-501.
5. Gerli R, Lunardi C, Pitzalis C. Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis. Rheumatology Oxford 2002;41:1341-5.
6. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
7. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
8. Roblot P, Morel F, Lelievre E, Gascan H, Wijdenes J, Lecron JC. Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy. J Rheumatol 1996;23:408-10.
9. Neurath MF, Hildner K, Becker C, et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis: a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999;115:42-55.
10. Rudwaleit M, Yin Z, Siegert S, et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 2000;59:311-4.